Ollers. The temperature was jumped to 30 more than about 30 s, and polymerization was followed turbidimetrically at 350 nM for 30 min. Every reaction set integrated a reaction mixture with out compound, as well as the IC50 was defined because the concentration of compound that inhibited the extent of assembly versus the handle right after 20 min at 30 . These values have been obtained by interpolation involving the actual experimental values.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptSupplementary MaterialRefer to Internet version on PubMed Central for supplementary material.AcknowledgmentsThe authors are grateful for the National Cancer Institute of the National Institutes of Wellness (grant no. 5R01CA140674 to K.G.P. and M.L.T.) and Oxigene Inc. (grant to K.G.P. and M.L.T.) for their financial support of this project, and to the NSF for funding the Varian 500 MHz NMR spectrometer (grant no. CHE- 0420802). The content material is solely the duty on the authors and will not necessarily reflect the official views of the National Institutes of Well being.Bardoxolone The authors also thank Dr. James Karban and Dr. Michelle Nemec (Director) for the use of the shared Molecular Biosciences Center at Baylor University, Dr. Alejandro Ramirez (Mass Spectrometry Core Facility, Baylor University), and Dr. Kevin Klausmeyer (X-ray evaluation). The authors are grateful to Mr. Robert Harris, Ms. Priscilla Hor, and Ms. Siri Ancha for their worthwhile contributions for the synthesis of particular analogues.References and notes1. Jordan MA, Wilson L. Nat. Rev. Cancer. 2004; four:25365. [PubMed: 15057285] 2. Lopus, M.; Yenjerle, M.; Wilson, L. In Wiley Encyclopedia of Chemical Biology. Begley, TP., editor. Vol. 3. Hoboken, NJ: John Wiley and Sons, Inc.; 2008. p. 153-160. 3. Etienne-Manneville S. Curr. Opin. Cell Biol. 2010; 22:10411. [PubMed: 20031384] four. Wade RH. Mol. Biotechnol. 2009; 43:17791. [PubMed: 19565362] 5. Valiron O, Caudron N, Job D. Cell. Mol. Life Sci. 2001; 58:2069084. [PubMed: 11814057] 6. Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. Integr. Biol. 2011; 3:37587. 7. Tozer GM, Kanthou C, Baguley BC. Nat. Rev. Cancer. 2005; 5:42335. [PubMed: 15928673] eight. Hida K, Hida Y, Shindoh M. Cancer Sci. 2008; 99(3):45966. [PubMed: 18167133] 9. Kanthou C, Tozer GM. Exp. Opin. Ther. Targets. 2007; 11(11):1443457. ten. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM.3,3′-Diindolylmethane Clin.PMID:24059181 Cancer Res. 2005; 11:41620. [PubMed: 15701823] 11. Dougherty, GJ.; Chaplin, DJ. Vascular Disruptive Agents for the Treatment of Cancer. Meyer, T., editor. New York: Springer; 2010. p. 1-27.ch. 1 12. Siemann, DWin. Vascular-Targeted Therapies in Oncology. Siemann, D., editor. London, UK: John Wiley Sons; 2006. p. 1-8.ch. 1 13. Patil SA, Patil R, Miller DD. Future Med. Chem. 2012; 4(16):2085115. [PubMed: 23157240] 14. Weisenberg RC, Borisy GG, Taylor W. Biochemistry. 1968; 7:4466477. [PubMed: 5700666] 15. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Experientia. 1989; 45(two): 20911. [PubMed: 2920809] 16. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. J. Nat. Prod. 1987; 50(1):11931. [PubMed: 3598594] 17. Hasani A, Leighl N. Clinical Lung Cancer. 2011; 12(1):185. [PubMed: 21273175]Bioorg Med Chem. Author manuscript; accessible in PMC 2014 November 01.MacDonough et al.Page18. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC. J. Clin. Oncol. 20.